Atypical clinical manifestation and protracted latency are observed in the emerging variant of checkpoint inhibitor-associated bullous pemphigoid.

MLA

Kridin, Khalaf, and Christoph M. Hammers. “Atypical Clinical Manifestation and Protracted Latency Are Observed in the Emerging Variant of Checkpoint Inhibitor-Associated Bullous Pemphigoid.” The British Journal of Dermatology, vol. 187, no. 6, Dec. 2022, pp. 843–44. EBSCOhost, https://doi.org/10.1111/bjd.21882.

APA

Kridin, K., & Hammers, C. M. (2022). Atypical clinical manifestation and protracted latency are observed in the emerging variant of checkpoint inhibitor-associated bullous pemphigoid. The British Journal of Dermatology, 187(6), 843–844. https://doi.org/10.1111/bjd.21882

Chicago

Kridin, Khalaf, and Christoph M Hammers. 2022. “Atypical Clinical Manifestation and Protracted Latency Are Observed in the Emerging Variant of Checkpoint Inhibitor-Associated Bullous Pemphigoid.” The British Journal of Dermatology 187 (6): 843–44. doi:10.1111/bjd.21882.